WRF
CSTL icon

Waddell & Reed Financial’s Castle Biosciences CSTL Stock Holding History

Waddell & Reed Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$20.3M Buy
+296,891
New +$22.3M 0.04% 366

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $774M AUM 40.73% 1-Year Est. Return

Waddell & Reed Financial's CSTL Position: Q1 2021 in Review

Waddell & Reed Financial opened a new position in Castle Biosciences (CSTL) in Q1 2021: 296,891 shares worth $20.3M. The stake represents 0.04% of the portfolio and ranks #366 among its holdings.

175 funds tracked by Wall St. Rank hold CSTL as of Q1 2021.

  • Waddell & Reed Financial held 296,891 shares of Castle Biosciences worth $20.3M as of Q1 2021.
  • Castle Biosciences was a new Waddell & Reed Financial position in Q1 2021.
  • Castle Biosciences made up 0.04% of Waddell & Reed Financial's portfolio in Q1 2021, its #366 holding.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.